Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... with sulfonylureas in patients with type 2 diabetes Begin clinical trials on at least one ... diseases, including obesity, at the American diabetes Association (ADA) scientific sessions. ... presented data on a number of other promising new diabetes and anti-obesity targets demonstrating that ...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... Pipeline of Drugs For People with Type 1 diabetes - NEW YORK, Aug. 5 /PRNewswire-USNewswire/ -- The Juvenile diabetes Research Foundation said today that it has ... Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform. The ...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

... activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK ... biotech company like Mercury. diabetes is a major cause of morbidity and mortality by ... transaction by Katan Associates. About diabetes ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... medicine is stopped. High blood sugar and diabetes have been reported with INVEGA((R)) SUSTENNA(TM) and similar medicines. If you already have diabetes or have risk factors such as being overweight or ... and during the treatment. The complications of diabetes can be serious and even life-threatening. Call ...

Diabetes Gene Raises Odds of Lower Birth Weight

... shown to be involved in the development of type 2 diabetes also predisposes children to having a lower birth ... prenatal events may set the stage for developing diabetes in later childhood or adulthood. ... July 10 in the online version of the journal diabetes . "It's a bit unusual to find a gene ...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

... 2008 FDA Guidance titled, "Guidance for Industry: diabetes Mellitus -- Evaluating Cardiovascular Risk in New ... ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. ACTOS has not been ... ankles, anemia, and weight gain. Patients with diabetes should have regular eye exams. If you experience ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes medications. This 26-week open-label clinical ... doses of Lantus in 467 patients with type 2 diabetes taking stable doses of metformin alone or in ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... Julio Rosenstock, MD, Director of the Dallas diabetes and Endocrine Center at Medical City and also ... Hagedorn insulin (NPH) in patients with type 2 diabetes mellitus. This was an open-label, 5-year, ... mean baseline HbA1c 8.4 vs 8.3% (glargine vs NPH) diabetes duration 11 years, and about 70% of the ...

Spherix Announces Positive Phase 2 Study Results

... CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and ... in reducing HbA1c, a key indicator of Type 2 diabetes that monitors glycated hemoglobin in the blood. ... with no known contraindications to current Type 2 diabetes treatments, continues to lead us to believe that ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... milestone for MacroGenics and for the type 1 diabetes research community," stated Scott Koenig, M.D., ... may be easier to control. About Type 1 diabetes Type 1 diabetes is an autoimmune disease in which the body's ...

The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide

... comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results ... Buse, chief of endocrinology and director of the diabetes Care Center at the University of North Carolina ... mmol/L vs -0.60 mmol/L) in this typical type 2 diabetes population. The study comprised 464 patients who ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... (FDA's) guidance for evaluating CV risk in type 2 diabetes agents. These findings were presented at the 69th Annual Scientific Sessions of the American diabetes Association (ADA) in New Orleans. In the ... at Amylin. "Given that people living with diabetes have two- to four-times greater risk of ...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

... at the 69th Scientific Sessions of the American diabetes Association (ADA), which is continuing until June ... antibody, in new onset autoimmune type 1 diabetes patients. About the DEFEND Study ... . About Type 1 diabetes ...

Research: Popular Diabetes Medications Associated with Increase in Bone Fractures

... -- Research presented at the American diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; ... body of evidence informing the clinical care of diabetes patients. "Diabetes is one of the greatest ...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

... answer the question of whether all patients with diabetes and multi-vessel CAD might be better treated with ... Intensive surveillance of diabetes patients works. When the blood sugar levels of ... in the early years of this trial. diabetes patients must be screened for CAD. Many ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... 69th Annual Scientific Sessions of the American diabetes Association (ADA) in New Orleans. A New Drug ... unmet need for treating patients with type 2 diabetes with just one dose per week." Study Design ... 223+/-41 pounds, BMI 34.8+/-4.8 kg/m squared, diabetes duration 7.1+/-5.3 years. Significant ...

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162

... 69th Annual Scientific Sessions of the American diabetes Association (ADA) showed that once-daily ... "Even with available treatments, many type 2 diabetes patients still struggle to control their blood ... lasting weight loss. Many currently available diabetes treatments lead to weight gain, a concern for ...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

... New Phase II data presented today at the American diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly ... hypoglycemia. "Despite a range of available diabetes therapies, over half of patients with type ...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

... rapid acting insulin presented at the American diabetes Association's 69th Scientific Sessions NEW ... The data were presented today at the American diabetes Association's 69th Scientific Sessions. ... for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. ...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

... Insulin Glulisine on Glycemic Control in Type 2 diabetes Patients on Insulin Glargine and Oral Drugs," ... 69th Annual Scientific Sessions of the American diabetes Association (ADA). The study was a ... BMI 37 kg/m squared, A1C 7.9%, FPG 120 mg/dl, and diabetes duration of 10 years. In all groups, A1C ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

... data will be presented as part of the American diabetes Association's (ADA) 69th Annual Scientific ... the hope they could provide to the millions of diabetes patients who are struggling to maintain tight ... II study of LY2189265, 262 patients with type 2 diabetes who were suboptimally controlled on at least two ...

Boehringer Ingelheim Unveils Diabetes Pipeline

... compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating ... 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American diabetes Association (ADA) Scientific Sessions in New ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... Pivotal BLOOM Trial Presented at the American diabetes Association's 69th Scientific Sessions Expand on ... lorcaserin for weight management, at the American diabetes Association's 69th Scientific Sessions. ... for Overweight and Obesity Management in diabetes Mellitus), and is planned to enroll a total of ...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

... Two-year study presented at the American diabetes Association's 69th Scientific Sessions shows ... according to data presented today at the American diabetes Association's 69th Scientific Sessions. Results ... for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... trial results presented today at the American diabetes Association annual meeting show that overall ... Cardiac Outcomes and Regulation of Glycaemia in diabetes (RECORD) study, which was sponsored by ... compared to the most commonly used diabetes medicines, metformin and sulfonylurea, which have ...

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... if therapy is stopped. High blood sugar and diabetes have been reported with RISPERDAL(R) CONSTA(R) ... medications. If the person being treated has diabetes or risk factors such as being overweight or a ... with RISPERDAL(R) CONSTA(R). Complications of diabetes can be serious and even life threatening. If ...

Type 2 Diabetes: An Epidemic Among America's Youth

... With the number of children suffering from type 2 diabetes growing at an alarming rate, physicians gathered ... ) "Type 2 diabetes is extremely complex," said A. Jay Cohen, MD, ... order to identify the children at risk for type 2 diabetes and to demonstrate the effectiveness of lifestyle ...

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient

... 18 /PRNewswire-USNewswire/ -- When treating the diabetes patient, doctors discussed how a "one size fits ... information on type 1 and type 2 diabetes, diabetes complications, and tips on how diabetes patients can best prepare for disaster. ACE ...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

... Chapter - Bay State Branch of the Juvenile diabetes Research Foundation (JDRF), the leader in setting the agenda for diabetes research worldwide and the largest charitable ... Corporation, as Honoree while the Nancy Jones diabetes Champion Award will be given to U.S. Senator ...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

... to the commonly accepted theory of how leading diabetes drugs work and support our theory surrounding ... prevent the otherwise inexorable progression of diabetes and its complications." Colca and Rolf ... for late 2009. According to the American diabetes Association, approximately $1 in every 10 health ...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

... drug-eluting stents in patients with and without diabetes in a real-world setting. The JACC article ... no increased risk of restenosis for patients with diabetes as compared to those without diabetes. Both the ... restenosis was 1.23 times higher in patients with diabetes than in patients without diabetes. In patients ...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

... Clinical Endocrinologists (AACE) and the American diabetes Association (ADA) are calling for major changes ... of Endocrine Practice (Link here ) and diabetes Care (Link here ), come at a time when ... trials in critically ill patients in ICUs with diabetes or elevated blood glucose levels have failed to ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... Prevents Onset of Early Kidney Disease in Type 2 diabetes Patients SAN FRANCISCO, May 8 /PRNewswire/ ... onset of microalbuminuria in patients with type 2 diabetes (T2DM). Microalbuminuria is an early sign of ... benefits across a wide range of patients with diabetes classified from normotension to hypertension, and ...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

... Blacks (20.7/11 mm Hg) and patients with type 2 diabetes (21.5/12.6 mm Hg). AZTEC was the first time ... patient populations, such as patients with type 2 diabetes and Blacks." During the study, AZOR ... of 144.2/85.7 mm Hg. Patients with diabetes Seventy five percent of adults diagnosed ...

Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity

... seen across our phase 2 and phase 3 obesity and diabetes Qnexa trials to date, coupled with the positive ... lowering blood pressure and reducing the risk of diabetes and heart disease. About Qnexa(TM) ... obesity therapy being developed to address type 2 diabetes as well as weight loss. In phase 2 and phase 3 ...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

... Exenatide once weekly is an investigational diabetes therapy that is injected subcutaneously once a ... many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control ... study will also evaluate efficacy in the type 2 diabetes patients. The trial began this month and initial ...

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

... delivery of exenatide for the treatment of type 2 diabetes HAYWARD, Calif., April 24 /PRNewswire/ -- ... involves the treatment of 44 patients with type 2 diabetes for a period of 4 weeks. (Logo: ... this important treatment candidate for type 2 diabetes patients from an idea to clinical stage ...

New Weight Loss Hope for People with Diabetes

... School of Medicine, people with Type 2 diabetes on NutriSystem D lost as much as 16 times more ... beneficial in helping people with Type 2 diabetes control their blood sugar levels, maintain good ... of the disease. For people with Type 2 diabetes who have struggled to lose weight in the past, ...

Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout

... of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. ... 24,000 new cases of blindness each year, making diabetes the leading cause of new cases of blindness in ... of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. ...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

... of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes medications. This 26-week clinical study ... or pioglitazone, two commonly prescribed oral diabetes medications, in 491 patients with type ...